Nirogacestat Hydrobromide

Phase 2

CChildren's Oncology Group

Nirogacestat Hydrobromide is one of 2 therapeutic programs targeting Desmoid Fibromatosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Desmoid FibromatosisActive, not recruiting

Desmoid FibromatosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Desmoid Fibromatosis

#DrugCompanyPhaseTrials

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 2

1 2

Nirogacestat Hydrobromide

CChildren's Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 2Active, not recruiting

Desmoid Fibromatosis

NCT04195399

Clinical

Trials by Indication[1]

Desmoid Fibromatosis1 trial

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT04195399·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nirogacestat Hydrobromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nirogacestat Hydrobromide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Children's Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CChildren's Oncology Group

Nirogacestat Hydrobromide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Desmoid Fibromatosis1 trial

References

Drug Info

Quick Facts

Related News